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Abstract
The involvement of the gut microbiota in metabolic disorders, and the ability of whole grains to
affect both host metabolism and gut microbial ecology, suggest that some benefits of whole
grains are mediated through their effects on the gut microbiome. Nutritional studies that assess

the effect of whole grains on both the gut microbiome and human physiology are needed. We
conducted a randomized cross-over trial with four-week treatments in which 28 healthy humans
consumed a daily dose of 60 g of whole-grain barley (WGB), brown rice (BR), or an equal
mixture of the two (BR+WGB), and characterized their impact on fecal microbial ecology and
blood markers of inflammation, glucose and lipid metabolism. All treatments increased
microbial diversity, the Firmicutes/Bacteroidetes ratio, and the abundance of the genus Blautia in
fecal samples. The inclusion of WGB enriched the genera Roseburia, Bifidobacterium and
Dialister, and the species Eubacterium rectale, Roseburia faecis and Roseburia intestinalis.
Whole grains, and especially the BR+WGB treatment, reduced plasma interleukin-6 (IL-6) and
peak postprandial glucose. Shifts in the abundance of Eubacterium rectale were associated with
changes in the glucose and insulin postprandial response. Interestingly, subjects with greater
improvements in IL-6 levels harbored significantly higher proportions of Dialister and lower
abundance of Coriobacteriaceae. In conclusion, this study revealed that a short-term intake of
whole grains induced compositional alterations of the gut microbiota that coincided with
improvements in host physiological measures related to metabolic dysfunctions in humans.
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Introduction
Obesity is associated with an increased risk in cardiovascular disease, type-2 diabetes, nonalcoholic fatty-liver disease and some cancers, and constitutes a major health concern worldwide
(Cornier et al., 2008; Hu, 2011). A diet high in whole grains and dietary fibers has been shown to
improve metabolic parameters related to these metabolic disorders (Liu et al., 1999; Fung et al.,
2002; Liu et al., 2003; Murtaugh et al., 2003; Jensen et al., 2004; Nettleton et al., 2008). The
mechanisms responsible for the benefits of whole grains are not completely understood. It has
been proposed that the dietary fiber present in whole grains increases the viscosity of the digesta
and binds to bile acids in the small intestine, thus contributing to decreased sugar and lipid
(cholesterol) absorption (Behall et al., 2004; Alminger and Eklund-Jonsson, 2008). In addition,
phytochemicals and other bioactive compounds in whole grains might provide metabolic benefits
(Adom and Liu, 2002; Nilsson et al., 2006; Harris and Kris-Etherton, 2010). Furthermore, the
metabolic inflammation associated with obesity and related diseases is now considered to trigger
metabolic dysfunctions (Gregor and Hotamisligil, 2011), and the benefits of whole grains might
be due to an anti-inflammatory action (Nilsson et al., 2008b; Rosén et al., 2011). In this respect,
bacterial fermentation of undigestible constituents of whole grains in the gastrointestinal tract has
been suggested to be partly responsible for the benefits of whole grains (Nilsson et al., 2008a;
North et al., 2009; Harris and Kris-Etherton, 2010).
A consideration of the gut microbiome in the context of the health effects of whole grains has
become especially relevant in light of recent research that indicated an etiological role of gut
bacteria in metabolic disorders. Obesity and type 2 diabetes have been linked to alterations in the
intestinal microbiota in both the humans and animal models (Ley et al., 2006; Turnbaugh et al.,
2006; Cani et al., 2007; Larsen et al., 2010; Vijay-Kumar et al., 2010). If these aberrations
contribute to human disease is still unclear, but pathophysiological indicators are reduced in

animal models when animals are kept germ-free or when treated with antibiotics, and
manifestations of disease can be transmitted through the gut microbiota (Ley et al., 2005; Cani et
al., 2008; Vijay-Kumar et al., 2010; Henao-Mejia et al., 2012). Proposed mechanisms by which
microbiota contribute to metabolic aberrations are the induction of lipolysis leading to increased
fat storage (Bäckhed et al., 2007), hepatic de-novo synthesis of triglycerides (Bäckhed et al.,
2004) and the alteration of bile acid metabolites with consequences to lipid metabolism in the
host (Claus et al., 2011). Furthermore, the gut microbiome might exacerbate the systemic
inflammation associated with obesity and related metabolic disorders (Hotamisligil, 2006; Ding
et al., 2010), possibly through the induction of endotoxemia driven by lipopolysaccharide
translocation through the intestinal epithelium (Cani et al., 2007; Amar et al., 2008; Cani et al.,
2008; Li and Hotamisligil, 2010).
The interplay between the gut microbiota and host metabolism and the ability of whole grains to
affect both of these aspects suggest that one mechanism by which whole grains confer their
benefits might be through a modulation of the gut microbiome. Recent research has revealed that
the composition and metabolism of the gut microbiota can be modulated through prebiotics and
fiber (Flint et al., 2007; Louis et al., 2007), and these carbohydrates have been shown to improve
metabolic markers in experimental models (Cani et al., 2007; Neyrinck et al., 2011). Despite
these encouraging findings, human studies that investigate the effects of whole grains and cereal
fibers on host metabolism have neglected, until now, to characterize the gut microbiome and
explore its potential contribution to health improvements (Tilg and Kaser, 2011). In addition,
although the effect of fiber on the gut microbiota has been recently studied in experimental
animals (Neyrinck et al., 2011; Van den Abbeele et al., 2011), information on how whole grains
impact human gut microbiome composition is lacking.
The aims of this study were to characterize the impact of the incorporation of whole grains to an
otherwise unrestricted diet on gut microbial ecology in healthy human subjects, and to
investigate whether a connection with metabolic and immunological improvements exists. For
this purpose, we performed a human crossover study with three four-week whole grain
treatments, and collected fecal and blood samples at baseline and at the end of each treatment.
The effect of whole grains on fecal microbiota composition was characterized by pyrosequencing
of 16S rRNA gene tags, and inflammatory and metabolic markers related to metabolic
dysfunctions in humans were measured in blood samples. The molecular characterization of
fecal microbiota in parallel to host phenotyping allowed an investigation of associations between
diet-induced metabolic changes and shifts in the gut microbiome.

Materials and methods
Subjects
The human trial was approved by the Institutional Review Board of the Kansas State University
(IRB Approval Number: 5298), and written informed consent was obtained from all subjects.
Healthy participants (see Supplementary materials for inclusion/exclusion criteria) were
recruited through leaflets distributed on-campus by the College of Human Nutrition at the

Kansas State University, Manhattan, KS. Twenty-eight participants, 17 females and 11 males
(age 25.9±5.5 years), took part in the study.

Test meals
Whole grain Prowashonupana Barley (Sustagrain Barley Quick Flakes, ConAgra Mills, Omaha,
NE, USA) and whole-grain brown rice (Insta Grains Brown Rice Flakes, Briess, Chilton, WI,
USA) flakes were used in this study. Three test meals with different amounts of total dietary
fiber were included: a barley treatment (WGB), consisting of 60 g of barley (18.7 g total dietary
fiber); a brown rice and barley treatment (BR+WGB), consisting of 30 g each barley and BR
(11.5 g total dietary fiber); and a BR treatment, consisting of 60 g of BR (4.4 g total dietary
fiber). Subjects were provided with individual bags containing a daily dose of the corresponding
treatment (60 g of flakes). Nutritional information of the whole-grain flakes used in the study is
available in the Supplementary materials and Supplementary Table S1.

Study design
The study was conducted as a randomized crossover trial over 17 weeks (Figure 1). The first
week served as a baseline period, after which each subject underwent three four-week dietary
treatments (BR, BR+WGB, WGB) in random order, and interspaced by two-week washout
periods. The study was conducted under free-living conditions, and no dietary restrictions were
imposed except that subjects were expected to be non-vegetarian. Subjects were instructed to
consume the 60 g of flakes daily either plain, with yogurt or with milk, without time restrictions.
Weekly symptom diaries were completed by the subjects in which they self-reported bowel
movement, discomfort, flatulence, bloating, stool consistency and general well-being on a scale
from 1 to 5 (1 being optimal/normal and 5 worst/abnormal).

Figure 1 Experimental design. Time line of the randomized crossover trial. Three four-week
dietary treatments were assessed in succession. The treatments were interspaced by two-week
washout (WO) periods. Blood and stool samples (indicated by arrows) were collected during the
baseline (BL) and at the end of each treatment period.

Subject parameters and determination of metabolic and immunological markers
Subject parameters were measured at the Human Metabolism Laboratory at Kansas State
University. Total body composition was assessed at baseline with dual-energy X-ray
absorptiometry (Prodigy GE-Lunar, GE, Waukesha, WI, USA). Blood samples were drawn at
baseline and at the end of each dietary treatment after a 12 h overnight fast. An initial blood
sample was drawn (time 0). A standard drink containing 75 g of glucose (Fisher Scientific,

Pittsburg, PA, USA) was consumed within 10 min, and blood samples were collected at 15, 30,
45, 60, 90 and 120 min for the determination of postprandial glucose and insulin responses.
Blood was immediately placed in tubes containing K2-EDTA (Vacutainer, BD, Franklin Lakes,
NJ, USA) and centrifuged at 1000–1500x g for 13 min at 5–10 °C. Aliquots of plasma were
transferred into tubes for storage at −80 °C until further testing.
Glucose and insulin were measured in plasma samples in duplicate using an automated analyzer
(YSI 2300, YSI Life Sciences, Yellow Springs, OH, USA) and the Human Gut Hormone
Immunoassay kit (Milliplex, EMD Millipore, Billerica, MA, USA) with a dual laser flow
cytometer (Luminex, EMD Millipore, Billerica, MA, USA), respectively. A lipid profile,
consisting of total cholesterol, high-density lipoprotein (HDL) and non-HDL cholesterol was
performed on the preprandial samples (time 0) using the Cholestech LDX System (Alere,
Waltham, MA, USA). Three markers of inflammation were measured in plasma samples by
enzyme-linked immunosorbent assays (in duplicate): lipopolysaccharide-binding protein (LBP)
(USCN Life Science and Technology, Huston, TX, USA), high-sensitive C-reactive protein (hsCRP) (Symansis, Timaru, New Zealand), and interleukin 6 (IL-6) (R&D Systems, Minneapolis,
MN, USA).
Short-chain fatty acids were quantified in fecal samples by gas chromatography as described in
the Supplementary materials.

Compositional analysis of the fecal microbiota by pyrosequencing
Despite the fact that fecal samples represent microbial communities that are shed from the gut
and not resident, they provide a good overview over the microbiota present in the distal colon,
and are the most practical samples that can be obtained from subjects participating in nutritional
trials. Subjects provided fecal samples within 24 h of blood sampling and 2 h of defecation. Fecal
material and 1:10 fecal homogenates in phosphate-buffered saline (pH=7) were immediately
frozen (−80 °C) and stored until further processing. Bacterial DNA was extracted from fecal
homogenates as described by Martínez et al. (2010), using the QIAamp DNA Stool Mini Kit
(Qiagen, Valencia, CA, USA) in combination with enzymatic and mechanical cell lysis.
Pyrosequencing of amplicons obtained by PCR with universal primers targeting the V1–V3
region of the 16 S rRNA gene was performed as previously described (Martínez et al., 2010),
using the 454 Genome Sequencer FLX with GS FLX Titanium series reagents at the Core for
Applied Genomics and Ecology (University of Nebraska). Sequences obtained during this study
are deposited in the MG-RAST server under the accession numbers 4498555.3, 4498556.3 and
4498557.3.
Sequence processing was performed combining features of QIIME (Caporaso et al., 2010) and
the Ribosomal Database Project pipeline (Cole et al., 2009). Three-thousand quality-controlled
sequences per sample were randomly selected and used for taxonomic classification. Sequences
were assigned to a bacterial phylum, family and genus using the Classifier tool of the Ribosomal
Database Project (Wang et al., 2007). In addition, sequences were assigned to operational
taxonomic units with 97% sequence homology as described in the Supplementary materials.
Chao1 species richness estimator, and Shannon's and Simpson's (defined as 1-Dominance)
diversity indices were computed with QIIME.

Query for genes encoding β-glucanases in genomes of human gut microbes
Bacterial genomes available in the Joint Genome Institute database were used to identify largebowel associated bacteria with β-glucanase encoding activity. The integrated microbial genomes
platform of Joint Genome Institute was used to conduct this survey. A list of the strains included
in the survey is presented in the Supplementary materials. For the species identified to contain βglucanase genes, their abundance in the fecal microbiota of our subjects was quantified by
BLASTn.

Statistics
Results are presented as means±s.d. Differences in bacterial taxa and host phenotypes among
treatments were determined by one-way analysis of variance with repeated measures in
combination with Tukey's post-hoc tests, and P<0.05 was considered statistically significant. If
the data were not normally distributed, values were subjected to transformations such as square
root or logarithm with base 10 to achieve normality. If normality could not be achieved through
transformations, the non-parametric Kruskal-Wallis test was performed. When only two groups
of data were compared, Student's t-tests were performed. Correlations between host parameters
and bacterial populations were assessed by Pearson's correlation tests using GraphPad Prism
version 5.00 (GraphPad Software, La Joya, CA, USA). Associations between inflammatory
markers and gut microbiome composition were also analyzed through linear models using SAS
(SAS Institute Inc., Cary, NC, USA). Additional information on the statistical methods can be
found in the Supplementary materials.

Results
Physiologic, metabolic and microbiome characteristics of the study population
Twenty-eight volunteers, 11 males and 17 females, participated in the nutritional trial, and
subjects' parameters are presented in Table 1. Based on percent body fat, 13 subjects were
classified as overweight, using as cutoff values >31% body fat for women and >25% for men.
This Metabolic and immunological markers included in the study were plasma fasting glucose
and insulin levels, glycemic and insulin postprandial response, a lipid panel (total cholesterol,
HDL, non-HDL), and inflammatory markers (hs-CRP, IL-6 and LBP). The rationale for the
inclusion of these markers is their suitability in determining the progression of metabolic
aberrancies and the risk of cardiovascular disease (Schumann et al., 1990; Spranger et al., 2003;
Cardellini et al., 2005; Ridker, 2009), and their association with obesity (Sun et al., 2010).
Accordingly, positive correlations between body fat and all three inflammatory markers were
observed (Figures 2a–c). LBP and hs-CRP were highly correlated (r=0.90, P<0.0001) (Figure
2d). The linear model identified body fat as a significant factor affecting IL-6 (P<0.01), hs-CRP
(P<0.0001) and LBP (P<0.0001). Furthermore, significant positive correlations existed between
IL-6 and postprandial glucose response (Figure 2a). Together, these associations substantiate the

link between adiposity, a low-grade systemic inflammation, and glucose metabolism
(Hotamisligil, 2006).

Figure 2
Associations among host physiological characteristics and their correlation with bacterial
populations in fecal samples at baseline. Heatmap displaying correlation coefficients between
metabolic and physiological parameters of the study population at baseline (a). Correlations
between hs-CRP with body fat (b), LBP with body fat (c), hs-CRP and LBP (d), hs-CRP and
Ruminococcaceae (e), LBP with Ruminococcaceae (f) and Oscillibacter with postprandial AUC
glucose (g). Pearson's correlation (r) and the corresponding P-values are presented.

Table 1. Baseline characteristics of the 28 subjects, and differentiated by gender and
percent body fat (values are presented as mean±s.d.)
Overall

Body fata

Gender

All subjects
(n=28)

Male
(n=11)

Female
(n=17)

Age

25.9±5.4

26.7±5.4

25.4±5.8

Weight (kg)

72.3±18.3

87.7±17.1

BMI
(kg m−2)

25.1±4.5

Body fat
mass (kg)
Body fat (%)

P- Overweight Normoweight Pvalue
(n=13)
(n=15)
value
NS

28.6±6.6

23.6±3.0

<
0.05

62.3±10.5

<
79.7±19.5
0.001

65.9±14.9

<
0.05

27.4±4.8

23.6±3.7

<
0.05

27.9±4.4

22.7±3.0

<
0.001

20.8±10.3

20.2±11.6

21.2±9.8

NS

29.7±8.1

13.1±3.6

<
0.001

29.6±11.0

22.8±8.5

34.0±10.8

<
0.01

39.2±7.4

21.3±6.3

<
0.001

Total
cholesterol

4.86±1.12

4.07±0.69

5.22±1.67

<
0.01

4.76±1.26

4.75±1.07

NS

Non-highdensity
lipoprotein

3.13±1.03

2.78±0.74

3.29±1.38

NS

3.23±1.21

2.94±0.85

NS

Highdensity
lipoprotein

1.65±0.42

1.30±0.28

1.84±0.57

<
1.53±0.45
0.001

1.65±0.42

NS

Fasting
plasma
glucose
(mmol l−1)

5.17±0.74

5.14±0.72

5.15±1.42

4.94±0.40

NS

Cholesterol
(mmol l−1)

Fasting
plasma
insulin
(μlU ml−1)

NS

5.44±0.93

43.44±18.86 42.76±20.55 44.93±21.14 NS 49.77±19.92 40.34±18.38

NS

1.75±1.43 1.18±0.81
2.01±1.60
(0.06–5.17) (0.33–2.59) (0.06–5.17)

Inflammatory
markers
IL-6
(pg ml−1)
(min–max)
Hs-CRP
(mg l−1)
(min–max)
LBP
(μg ml−1)
(min–max)

1.69±2.24
(0.002–
7.039)

0.32±0.22
(0.052–
0.805)

2.38±2.46
(0.002–
7.039)

NS

2.29±1.34
(0.65–4.89)

1.28±1.33
(0.06–5.17)

NS

<
0.01

2.47±2.36
(0.115–
6.696)

0.97±1.87
(0.002–
7.039)

NS

15.09±19.85 4.42±3.03 20.91±22.41 < 23.98±24.90 7.48±8.60
(0.12–
(1.00–9.61)
(0.12–
0.01
(2.12–
(0.12–28.51)
88.05)
88.05)
88.05)

NS

Abbreviations: hs-CRP, high-sensitive C-reactive protein; IL, interleukin; LBP,
lipopolysaccharide-binding protein; NS, not significant.

a

Women with over 31% body fat, and men with over 25% body fat were considered as
overweight individuals. All others were considered lean.

Pyrosequencing revealed that the baseline fecal microbiota of the participants was dominated by
the phyla Firmicutes and Bacteroidetes, with lower proportions of Verrucomicrobia and
Actinobacteria, in agreement with previous molecular characterizations of the human fecal
microbiota (Ley et al., 2006; Martínez et al., 2010). We investigated whether associations
between host phenotypes and microbial populations existed (Supplementary Figure S1). No
significant correlation was observed between any bacterial group and body fat or BMI, although
overweight subjects harbored significantly lower abundances of Ruminococcaceae (10.8±5.4%
versus 17.9±9.9%, P<0.05) and Faecalibacterium (1.8±1.8% versus 3.7±2.5%, P<0.05). The
analysis revealed negative correlations between the family Ruminococcaceae and all the three
inflammatory markers at baseline (Figures 2e and f, and Supplementary Figure S1). Within this
family, the genera Faecalibacterium and Ruminococcus displayed negative correlations with hsCRP (r=−0.48, P<0.05, and r=−0.60, P<0.01, respectively). The analysis also revealed a
negative association between Oscillibacter and postprandial glucose area under the curve (Figure
2f). Regarding the markers of lipid metabolism, proportions of Bacteroidetes, Bacteroidaceae
and Bacteroides were positively correlated to plasma HDL values (r=0.54, P<0.05; r=0.56,
P<0.05; r=0.56, P<0.05; respectively) (Supplementary Figure S2).

Effects of whole grains on fecal microbial communities
Sequence data obtained by pyrosequencing were used to establish the effects of whole grains on
the gut microbiota composition. This analysis revealed that whole grains had a measurable effect
on gut microbiota composition. All three treatments significantly increased the bacterial diversity
measured by Shannon's and Simpson's indices but not by Chao1 (Supplementary Figure S3).
These results indicated an increase in community evenness (Shannon's and Simpson's), but not in
total species richness (Chao1).
In accordance to previous studies that assessed the effect of diet on the gut microbiome
(Martínez et al., 2010; Davis et al., 2011), substantial inter-individual variation was observed in
response to whole grains (Supplementary Table 2). Despite this variability, several diet-induced
shifts reached statistical significance in the entire study population. The proportion of the phylum
Firmicutes increased, while Bacteroidetes were reduced (Table 2). The decrease in Bacteroidetes
was largely caused by a reduction of the genus Bacteroides (Table 2).

Table 2
Abundance of dominant bacterial taxa (% of total microbiota) in fecal samples as
determined by 454 pyrosequencing (values are presented as mean±s.d.)
Baseline
BR
BR+WGB
WGB
P- Confirmatio
value n by linear
model
Phylum

Baseline

BR

BR+WGB

WGB

P- Confirmatio
value n by linear
model

Firmicutes

57.30±14.1 65.06±11.4 65.53±10.6 65.42±12.0 0.003
3
0a
4a
5a

Yes

Bacteroidetes

37.99±14.3 30.74±11.6 29.85±11.9 30.32±12.2
5
2a
3a
2a

0.01

Yes

Verrucomicrobia

1.82±1.98

1.34±1.53

0.68±0.80

0.59±0.80

NS

Yes

Actinobacteria

1.24±0.97

1.42±1.78

2.23±3.32

2.05±2.73

NS

Yes

Family
Bacteroidaceae

28.55±15.7 22.89±10.3 21.19±11.8 23.48±12.6 0.013
3
7
7a
2

Yes

Lachnospiraceae

22.21±7.90 22.62±7.91 23.11±6.56 22.65±7.63

NS

Yes

Ruminococcaceae 14.64±8.76 17.32±8.90 16.53±8.06 15.82±8.32

NS

Yes

0.001

Yes

Incertae Sedis
XIV

b

8.62±4.32

b

5.79±3.15

7.63±4.47

8.16±3.97

3.40±3.07

2.69±3.42

2.76±3.10

1.95±1.55a 0.022

No

2.97±9.24

2.34±6.56

3.59±10.10

2.39±6.50

NS

Yes

1.85±4.58

0.77±1.53

0.68±1.28

0.59±0.80

NS

Yes

Rikenellaceae

1.77±2.09

1.68±1.85

1.12±1.06

1.35±1.68

NS

Yes

Veillonellaceae

1.59±1.13

1.52±1.19

1.86±1.19

1.97±1.60

NS

Yes

Porphyromonadacea
e
Prevotellaceae
Verrucromicrobiace
ae

Genus
Bacteroides

28.55±15.7 22.89±10.3 21.19±11.8 23.48±12.6 0.022
3
7
7a
2

Yes

Blautia

5.68±3.15

7.61±4.47

8.14±3.97b

8.61±4.32b 0.001

Yes

Ruminococcus

4.20±4.91

5.35±5.05

4.171±5.75

3.46±4.32

NS

Yes

2.82±2.38

3.06±2.29

3.86±3.22

3.86±3.19

NS

Yes

Prevotella

2.79±8.89

1.99±6.24

3.34±9.84

2.02±6.30

NS

Yes

Dorea

2.59±2.01

3.12±2.22

3.08±1.80

2.75±1.86

NS

Yes

Parabacteroides

2.58±3.05

2.06±3.23

2.10±3.14

1.59±1.44

NS

Yes

Roseburia

1.98±1.35

1.70±1.25

2.42±1.58

3.06±2.91e

0.01

Yes

Faecealibacterium

Baseline

BR

BR+WGB

WGB

P- Confirmatio
value n by linear
model

Akkermansia

1.85±4.58

0.77±1.53

0.68±1.28

0.59±0.80

NS

Yes

Coprococcus

1.82±2.09

1.91±2.08

1.47±2.22

1.35±1.78

NS

Yes

Alistipes

1.76±2.08

1.67±1.85

1.11±1.05

1.34±1.67

NS

Yes

Oscillibacter

1.27±1.04

1.24±1.00

1.08±0.83

0.96±0.61

NS

Yes

Bifidobacterium

0.99±1.88

1.02±1.64

1.95±3.16

1.84±2.54d 0.011

No

Subdoligranulum

0.94±1.03

1.17±1.43

1.42±1.73

1.09±1.02

NS

Yes

d

Dialister

0.75±1.17

0.60±0.89

0.94±1.21

1.14±1.69

0.027

No

Odoribacter

0.26±0.24

0.28±0.35

0.28±0.41

0.15±0.18b 0.002

No

Operational Taxonomic Units (OTU number, closest hit in database, % identity with 16S rRNA
gene)
0.07±0.10b 0.001

1737,
Odoribacter
splanchnicus, 99%

0.15±0.14

0.13±0.18

0.15±0.24

No

679, Eubacterium
rectale, 94%

0.25±0.32

0.31±0.42

0.43±0.57 0.57±0.63b,e

<
0.000
1

Yes

956, Roseburia
faecis, 99%

0.12±0.17

0.06±0.07

0.26±0.31

0.53±0.92b,f

<
0.000
1

Yes

770, Roseburia
intestinalis, 100%

0.09±0.12

0.04±0.05

0.17±0.18d 0.30±0.42a,f

<
0.000
1

Yes

3, Blautia
wexlerae, 100%

1.07±0.78

1.58±1.11

1.49±0.98 1.82±1.14c,g

<
0.000
1

Yes

179-188, Blautia
spp.

1.81±1.13

2.38±1.69

2.75±1.75a

2.80±2.04b 0.006

Yes

44-19-1999-93,
2.48±2.67
Eubacterium
rectale, 98%
Open in a separate window

2.75±3.27

3.65±3.45 4.83±3.98a,e, 0.001

Yes

g

Abbreviations: BR, brown rice; NS, not significant; OUT, operational taxonomic unit; WGB,
whole grain barley.
Significantly different to baseline: aP<0.05, bP<0.01, cP<0.001.

Significantly different to BR: dP<0.05, eP<0.01, fP<0.001.
Significantly different to BR+WGB: gP<0.05.
The increase in Firmicutes was more comprehensive and shifts in the abundance of several taxa
were detected. All three dietary treatments increased the abundance of the genus Blautia and two
operational taxonomic units within this genus (Table 2), although significance was only achieved
when WGB was included in the treatment. Several compositional shifts were strictly associated
with the consumption of WGB, namely the genera Roseburia, Bifidobacterium and Dialister and
the species E. rectale, R. faecis and R. intestinalis (Table 2), and many of these taxa increased
gradually with WGB intake. The linear regression model confirmed all of these significant
changes except for the species Bifidobacterium, and Dialister. Other taxa clearly responded to
WGB, but because of inter-individual variation, these shifts did not reach statistical significance.
For example, Bacteroides coprocola, which was only detected in three subjects, showed a 10fold increase with WGB consumption in only two of the subjects (Supplementary Table S2).
Although both whole grains led to an equivalent increase in the Firmicutes/Bacteroides ratio, no
family or genus showed a significant increase for BR, suggesting that this test meal induced
diverse alterations in the gut microbiome that are not consistent among subjects.
No significant differences were detected in the amounts of short-chain fatty acids for any of the
treatments. It is possible that an increase in short-chain fatty acids could not be detected in fecal
samples they are for the most part absorbed in the gastrointestinal tract (Millet et al., 2010).

Distribution of β-glucanase genes in human gut microbes
WGB contains a high amount of β-glucans (14.1%), while none were detected in BR
(Supplementary Table S1). In order to test if the ability to hydrolyze β-glucans could explain the
specific shifts in the fecal microbiota induced through WGB, we investigated distribution of βglucanase genes in 112 strains originating from the human gut. This analysis revealed that βglucanase genes are present in a variety of gut bacterial species from a broad taxonomic range,
including ten Bacteroides, four Bifidobacterium, three Collinsella, two Clostridium, two
Coproccus, two Eubacterium, one Ruminococcus, two Roseburia, and one Akkermansia species
(Supplementary Table S2). Of these species, only E. rectale, R. faecis and R. intestinalis were
significantly increased through WGB, indicating that the mere presence of β-glucanase encoding
genes does not predict the changes in community composition in response to the diet.

Whole grain-induced metabolic and immunological changes
The daily consumption of 60 g of whole grains for 4 weeks improved immunological and
metabolic markers in the human subjects. The findings for the entire study population are shown
in Supplementary Table S3, and differentiated by gender and body fat in Supplementary Tables
S4 and S5. A significant decrease in plasma IL-6 levels for the BR+WGB treatment versus
baseline values was detected (Figure 3a). Quantitatively, this reduction was highest in
overweight subjects (Figure 3b). In women, all three treatments significantly reduced IL-6
(Figure 3c). The linear model analysis confirmed the anti-inflammatory effect of whole grains
and revealed a significant reduction of IL-6 for BR+WGB and WGB treatments (P<0.01,

P<0.05). Despite not achieving statistical significance due to high inter-individual variation, hsCRP plasma levels were halved during the BR+WGB period compared with the baseline
(Supplementary Tables S3-S5).

Open in a separate window
Figure 3
Immunological and metabolic improvements induced through whole-grain consumption. Plasma
IL-6 levels in the entire subject population (a), in overweight participants (b), and in females (c).
Maximum postprandial glucose levels in the entire subject population (d) and overweight
subjects (e) during the three treatments (BR, BR+WGB, WGB) and at baseline. *P< 0.05, **P<
0.01, §P< 0.1.
Whole-grain consumption significantly improved glucose and lipid metabolism. Postprandial
peak glucose levels were significantly lowered in overweight subjects during the BR+WGB
period (P<0.05), and the reduction approached significance in the entire study population
(P<0.1) (Figures 3d and e). Fasting glucose levels were significantly decreased in women and

overweight subjects, and in females, total cholesterol was significantly reduced (Supplementary
Tables S4 and S5).

Links between whole grain-induced metabolic improvements and fecal microbial
community structure
To determine whether effects of whole grains were related to the gut microbiome, a correlation
analysis was performed between bacterial shifts and changes in the metabolic markers that
occurred during the BR+WGB period. We focused the analysis on the BR+WGB treatment as it
induced the most significant metabolic improvements (Figure 3). This analysis revealed that
increases in the abundance of E. rectale were associated with improvements in the postprandial
glucose and insulin response (Supplementary Figures S4A and SB). The association between E.
rectale and maximum postprandial glucose levels approached significance (Supplementary
Figure S4C).
In addition, we categorized subjects into the three groups (terciles) according to the magnitude of
the improvements in IL-6, hs-CRP, fasting glucose and glucose peak through BR+WGB. The
baseline proportions of the bacterial groups between the three groups were compared. This
analysis revealed that the gut microbiota of subjects with the highest improvement in IL-6 (3rd
tercile) contained significantly higher percentages of Veillonellaceae (Figure 4a), and within this
family, the genus Dialister (Figure 4b). Conversely, Coriobacteriaceae were significantly
decreased in subjects with the highest improvement in IL-6 (Figure 4c). No significant
differences in microbiome composition were detected between the terciles generated for hs-CRP,
fasting glucose and postprandial glucose peak.

Figure 4
Abundance of specific taxa in subjects that showed differences in their IL-6 response to whole
grains. Subjects were classified into terciles according to the magnitude of the change in plasma
IL-6 levels induced by whole-grain consumption (BR+B treatment versus baseline). The
proportions of bacterial taxa in fecal samples during the baseline were compared in the three
terciles and significant differences existed in the proportions of Veillonellaceae (a), Dialister (b)
and Coriobacteriaceae (c) in fecal samples during baseline. *P< 0.05, **P< 0.01.

Gastrointestinal symptoms
Self-reported symptoms diaries revealed that 60 g of WGB significantly increased all the
gastrointestinal symptoms surveyed, especially flatulence, while 30 g caused only a slight
increase in flatulence (Supplementary Table S6). The addition of BR to the diet did not result in
any reported changes in symptoms.
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Discussion
The metabolic and immunological benefits of whole grains have been shown in various studies
(Fung et al., 2002; Behall et al., 2004; Jensen et al., 2004; Nilsson et al., 2006, 2008b), and a
contribution of the gut microbiome to these effects has been suggested (North et al., 2009).
However, the assessment of bacterial participation in these processes has been limited to
hydrogen breath measurements, and the effects of whole grains on the gut microbiome structure
have not been investigated. In this study, we showed that whole grains have a significant effect
on the composition of the fecal microbiota that coincided with metabolic and immunological
improvements in healthy human individuals.
All whole-grain test meals caused an increase in community diversity within the subjects, driven
by an increase in evenness of bacterial species. Therefore, WGB and BR seem to differ in their
effects on the gut microbiota when compared with prebiotics and dietary fibers, which have not
been shown to increase community diversity (Martínez et al., 2010; Davis et al., 2011; Van den
Abbeele et al., 2011). These differences might be due to compositional complexity of whole
grains, which contain a variety of carbohydrates, potentially affecting a wider scope of bacterial
taxa. Interestingly, a higher microbial diversity in fecal samples was also observed in children
from Burkina Faso, who consumed a diet high in whole grains, legumes and vegetables, when
compared with Europeans (De Filippo et al., 2010). In addition, weaning in human infants leads
to a drastic increase in diversity likely caused by the incorporation of more diverse arrays of
dietary carbohydrates (reviewed in Koropatkin et al., 2012). Therefore, it appears that bacterial
diversity in the gut can be increased by providing a broader range of undigestible substrates, and
our findings showed that this can be achieved by intake of whole grains.
This study revealed shifts in the fecal microbiota that were induced by both BR and WGB, while
others were specific to WGB intake. Both whole grains increased the Firmicutes/Bacteroidetes
ratio and the abundance of the genus Blautia. The overall shift in microbiota structure in favor of
an expansion of Firmicutes could be the result of an increased carbohydrate intake (Duncan et
al., 2008). However, in a previous study, we did not observe an increase in the
Firmicutes/Bacteroidetes ratio with the consumption of crackers containing resistant starches
(Martínez et al., 2010), although the dose of carbohydrates and fiber in these crackers exceeded
that of the whole-grain test meals. Interestingly, a decrease of Bacteroides was also shown to be
associated with a long-term consumption of diets rich in whole grains, dietary fibers and
vegetables in African children and US individuals (De Filippo et al., 2010; Wu et al., 2011).
These and our findings suggest that other components included in whole grains and other plantderived food products might influence community structure at the phylum level, specifically

decreasing Bacteroidetes. The reason for the increase in the genus Blautia through whole grains
might be due to a syntrophic effect. Blautia species are acetogenic and might benefit from the
production of hydrogen, which is a product of glycan fermentation, and, therefore, likely induced
by whole grain consumption (Nakamura et al., 2010; Koropatkin et al., 2012).
We detected several bacterial taxa that displayed a specific increase with WGB, several with a
clear dose response. This is likely due to its high content of β-glucans. Accordingly, the bacteria
that specifically responded to WGB harbor genes encoding for β-glucanases and utilize the
substrate in vitro (Hughes et al., 2008; Tasse et al., 2010). However, the in vivo findings cannot
solely be explained based on functional and genomic attributes of community members, as
Bacteroides species decreased during WGB consumption, but possess β-glucanase genes and can
utilize β-glucans in vitro (Crittenden et al., 2002; Tasse et al., 2010; Zhao and Cheung, 2011). A
possible explanation for the in vivo findings could entail preferences towards distinct β-glucan
structures and molecular weights. The β(1–4) to β(1–3) linkage ratio in barley is 2.3-3, while
Bacteroides species have been shown to especially possess β(1–3)-glucanase activity (Salyers et
al., 1977). Moreover, barley-derived β-glucan fractions of high molecular weight have also been
shown to be poorly fermented by Bacteroides (Hughes et al., 2008). However, previous human
trials with prebiotics and resistant starches have also revealed that the ability of a species to
utilize substrates in vitro does not predict population shifts in vivo (Martínez et al., 2010; Davis
et al., 2011; Koropatkin et al., 2012). Therefore, although the findings obtained suggest that βglucans are the main cause for the shifts in composition induced by WGB, the exact mechanisms
by which these changes are restricted to only a small number of taxa are likely to be due to
competitive interactions.
A main objective of this study was to determine whether the effects of whole grains on the gut
microbiome are associated with physiological benefits. The whole grains used in our study led to
immunological and metabolic improvements, especially when BR+WGB was consumed. Plasma
IL-6 was reduced, and a tendency for a decrease in plasma hs-CRP was detected. In addition to
this anti-inflammatory effect, an improvement in the glycemic response during BR+WGB
treatment was detected. Our findings are in agreement with previous research that established the
immunological and metabolic benefits of whole grains (Casiraghi et al., 2006; Kallio et al.,
2008; Nilsson et al., 2008b; Rosén et al., 2011). Most importantly, inflammation has been
identified as a main cause of metabolic disorders (Hotamisligil, 2006), and the anti-inflammatory
effect could provide a mechanism by which whole grains improve glucose metabolism.
The anti-inflammatory effect of whole grains might be mediated through its effect on the gut
microbiota. A remarkable positive correlation between LBP and hs-CRP was identified in our
study population, supporting a link between bacterial lipopolysaccharide and systemic
inflammation. The associations of these markers with body-fat support the hypothesis that
endotoxemia could contribute to obesity (Cani et al., 2007; Delzenne and Cani, 2011). WGB led
to an increase of bacterial taxa such as bifidobacteria and Roseburia, which have been suggested
to affect immune/inflammatory and metabolic functions in animal models (Cani et al., 2008;
Neyrinck et al., 2011). Although one could envision that these shifts might underlie the antiinflammatory effect of whole grains, no significant correlations between these taxa and
inflammatory markers were observed. However, shifts in the abundance of E. rectale induced
through the BR+WGB diet correlated with decreased postprandial glucose and insulin responses.

This organism produces butyrate, which might contribute to the immunological benefits of whole
grain consumption through its anti-inflammatory effects.
Interestingly, compositional differences at baseline were detected in the gut microbiome of
subjects that differed in the magnitude of their anti-inflammatory response to whole grains.
Subjects with the greatest reduction in plasma IL-6 concentration had significantly higher
proportions of Dialister and a lower abundance of Coriobacteriaceae. These bacterial groups
have been linked to chronic inflammation in previous studies. D. invisus and Coriobacteriaceae
have been shown to be reduced and increased in patients with Crohn's disease and colitic mice,
respectively (Clavel et al., 2009; Würdemann et al., 2009; Willing et al., 2010; Joossens et al.,
2011). The association of Dialister and Coriobacteriaceae with IL-6 response suggests that these
taxa may condition the capability of an individual to be immunologically responsive to whole
grains.
Before the start of the treatments, associations between bacterial groups, inflammatory state and
host metabolism were observed (Figure 3). Ruminococcaceae negatively correlated with markers
of inflammation and were more dominant in normoweight individuals. In addition, Bacteroidetes
positively correlated with HDL cholesterol. These observations could result from an impact of
these taxa on host physiology, and these associations provide a rationale to develop dietary
strategies that target Ruminococcaceae and Bacteroidetes to improve human metabolic and
immunological functions. However, host physiology (inflammatory state, cholesterol/bile acid
metabolism) might also shape the microbiome composition. If systemic inflammation and
cholesterol metabolism impact levels of Ruminococcaceae and Bacteroidetes, respectively, then
these interactions could explain the discrepancies related to an altered microbiome in obese
versus normoweight individuals (Ley et al., 2006; Duncan et al., 2008; Schwiertz et al., 2010).
Not obesity per se, but the associated inflammatory and metabolic aberrations could shape
microbiome composition and might cause variable and more complex patterns of dysbiosis.
This study has provided novel information about the relationship between whole grains, the gut
microbiota and host metabolism. Whole grain-induced alterations in the characteristics and
composition of the fecal microbiota coincided with immunological and metabolic benefits, and
the clear associations between the reduction of IL-6 and the presence of certain bacterial taxa
(Dialister, Coriobacteriaceae) indicate an important functional role of gut bacteria in the
physiologic effects of whole grains.
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Supplementary Information
Materials and Methods
Subjects
Interviews were conducted with the volunteers to explain the protocol, determine
whether they met the inclusion criteria, and record demographic data (age and
gender). Exclusion criteria were treatment with antibiotics within 3 months prior
to the beginning of the study or throughout its duration, being vegetarian,
exercise of more than 2 h weekly, a history of a chronic gastrointestinal disorder,
and the use of antihypertensive or lipid-lowering medications. Twenty-nine
healthy adults were recruited to participate in this study. One female subject was
excluded during the study as she required antibiotic treatment. Prior to the
beginning of the study, training sessions were held to explain the protocol to the
subjects.
Participants were instructed to incorporate the whole grains to their regular diet.
Other instructions included withholding from strenuous physical activity and
alcohol consumption on the day prior to blood drawing. Compliance with the
dietary treatments was encouraged by meeting with the subjects on a weekly
basis, on which occasions symptom diaries were collected and a bag with 7 daily
portions of the treatment flakes were distributed.

Test meals
Prowashonupana (Sustagrain® Barley Quick Flakes, ConAgra Mills) is a waxy,
hulless barley variety differing from standard barley in terms of its composition.
Prowashonupana contains exceptionally high levels of total dietary fiber (30%),
almost half being accounted for by β-glucan, and low levels of starch (<30%).
Brown rice has high amounts of soluble starch (around 75%) and small amounts
of total dietary fiber (around 7%). The processing of the barley flakes was as

follows, cleaned grain kernels were roller cut and steam treated at 100.5°C for 40
min to ensure microbiological safety and passed through flaking rolls to reduce
the pieces to a thickness of 0.020 ± 0.002 inches. The flakes were then cooled
down to room temperature, seized, screened and packaged. The brown rice
(Insta Grains® Brown Rice Flakes, Briess) was used as provided by the
manufacturer. It is currently unknown how the processing conditions of both
whole grains affect their functionality when compared to the unprocessed grains.
Digestible and resistant starches in the two flakes were measured in the products
(K-RSTAR, Megazyme, Ireland), as well as β-glucans (K-BGLU, Megazyme,
Ireland), and total dietary fiber (Andersson et al., 2009; AACC International,
2011). The nutritional data of the flakes is presented in Table S1.
DNA extraction from fecal samples
Fecal homogenates were transferred to bead beating tubes (Biospec products,
USA) containing zirconium beads (300 mg). Homogenates were centrifuged
(8,000×g for 5 min at room temperature) and the bacterial cell pellets were
washed twice by re-suspension in ice-cold PBS. 100 µl of lysis buffer (200 mM
NaCl, 100 mM Tris, 20 mM EDTA, 20 mg/ml Lysozyme, pH 8.0) containing 20
mg/ml of Lysozyme (Sigma-Aldrich) were added, and enzymatic lysis was
conducted at 37°C for 30 min. 1.6 ml of buffer ASL from QIAamp DNA Stool Mini
Kit (Qiagen, Germany) was added to each sample, after which the samples were
mechanically homogenized in a MiniBeadbeater-8 (BioSpec Products, USA) for 2
min at maximum speed. DNA was purified from 1.2 ml of the resulting
supernatant with the QIAamp DNA Stool Mini Kit following the manufacturer's
instructions.
Compositional analysis of the fecal microbiota by pyrosequencing
Sequences were binned by primer barcodes using QIIME (Caporaso et al.,
2010). Sequences that were shorter than 300 bp or longer than 550 bp,
contained one or more ambiguous nucleotides, had one or more mismatches to

the primer or barcode, had an average quality scores below 25, or contained
homopolymer runs over 6 bp, were removed. Chimeras were removed using the
Blast Fragments Algorithm included in QIIME.
OTU picking was performed by aligning sequences using the RDP Infernal
Alignment tool and clustered with the Complete Linkage Clustering algorithm
(RDP). As current OTU picking algorithms tend to generate too many clusters
(Ghodsi et al., 2011), abundance of OTUs identified to be associated with host
phenotypes or dietary treatments were confirmed using BLASTn.

For this

purpose, 5 representative sequences per OTU were taxonomically assigned and
aligned by ClustalW within their respective phylum. A distance matrix was
generated and phylogenetic trees (one per phylum) were constructed using the
Neighbor-joining algorithm (MEGA 4.0) (Tamura et al., 2007).

OTUs were

assigned visually as clusters within the phylogenetic trees, and membership was
confirmed by sequence comparisons and restricted to sequences with >97%
similarity. Consensus sequences were generated for each OTU. To quantify
each OTU, a local database was created in BioEdit (Hall, 1999) with all the
sequences. BLASTn with >97% similarity and >95% length overlap was used to
determine the number of sequences belonging to individual OTUs. OTUs that
shared a majority of their sequences were merged.
Genome queries for β-glucanase activity
The web-based Integrated Microbial Genomes (IMG) database of the Joint Genome
Institute (JGI) was used to identify gut organisms with beta-glucanase function. The

following bacteria were included: Bacteroides caccae ATCC 43185, Bacteroides
coprocola M16, Bacteroides dorei 5_1_36/D4, Bacteroides dorei DSM 17855,
Bacteroides

eggerthii

1_2_48FAA,

Bacteroides

eggerthii

DSM

20697,

Bacteroides finegoldii DSM 17565, Bacteroides fragilis 3_1_12, Bacteroides
fragilis 638R, Bacteroides fragilis NCTC 9343, Bacteroides fragilis YCH46,
Bacteroides intestinalis 341, Bacteroides ovatus 3_8_47FAA, Bacteroides ovatus

ATCC 8483, Bacteroides ovatus SD CC 2a, Bacteroides ovatus SD CMC 3f,
Bacteroides stercoris ATCC 43183, Bacteroides thetaiotaomicron VPI-5482,
Bacteroides

ATCC

uniformis

8492,

Bacteroides

vulgatus

ATCC

8482;

Bacteroides vulgatus PC510, Bacteroides xylanisolvens SD CC 1b, Bacteroides
xylanisolvens XB1A, Bifidobacterium adolescentis ATCC 15703, Bifidobacterium
adolescentis L2-32, Bifidobacterium catenulatum DSM 16992, Bifidobacterium
longum DJO10A, Bifidobacterium longum NCC2705, Bifidobacterium longum
subps. infantis 157F-NC, Bifidobacterium longum subps. infantis ATCC 16697,
Bifidobacterium longum subps. infantis JCM 1217, Bifidobacterium longum
subsp. longum ATCC 55813, Bifidobacterium longum subsp. longum BBMN68,
Bifidobacterium longum subsp. longum CCUG 52486, Bifidobacterium longum
subsp.

longum

Bifidobacterium

F8,

Bifidobacterium
subsp.

longum

pseudocatenulatum

DSM

longum

longum

20438,

Blautia

subsp.

KACC

longum

91563,

hansenii

VPI

JDM301,

Bifidobacterium
C7-24,

Blautia

hydrogenotrophica DSM 10507, Bryantella formatexigens I-52, Butyrivibrio
crossotus DSM 2876, Clostridiales sp. SM4/1, Clostridiales sp. 1_7_47FAA,
Clostridiales sp. SS3/4, Clostridiales sp. SSC/2, Clostridium bolteae ATCC BAA613, Clostridium butyricum 5521, Clostridium butyricum E4, Clostridium leptum
DSM 753, Clostridium ramosum VPI 0427, Clostridium sp. M62/1, Clostridium
spiroforme DSM 15579, Collinsella aerofaciens ATCC 25986, Collinsella
intestinalis DSM 13280, Collinsella stercoris DSM 13279, Coprococcus comes
ATCC 27758, Coprococcus eutactus ATCC 27759, Dialister invisus DSM 15470,
Dorea

formicigenerans

ATCC

27755,

Dorea

longicatena

DSM

13814,

Eggerthella lenta VPI 0255, Enterococcus fecalis ATCC 29200, Enterococcus
fecalis ATCC 4200, Eubacterium biforme DSM3989, Eubacterium cylindroides
T2-87, Eubacterium eligens ATCC 27750, Eubacterium hallii DSM 3353,
Eubacterium limosum KIST612, Eubacterium rectale ATCC 33656, Eubacterium
rectale DSM 17629, Eubacterium rectale M104/1, Eubacterium ventriosum ATCC
27560, Faecalibacterium prausnitzii KLE1255, Faecalibacterium prausnitzii A2165, Faecalibacterium prausnitzii L2-6, Faecalibacterium prausnitzii M21/2,
Faecalibacterium

prausnitzii

SL3/3,

Lachnospiraceae

1_1_57FAA,

Lachnospiraceae 1_4_56FAA, Lachnospiraceae 2_1_46FAA, Lachnospiraceae
2_1_58FAA,

Lachnospiraceae

3_1_46FAA,

Lachnospiraceae

3_1_57FAA,

Lachnospiraceae 4_1_37FAA, Lachnospiraceae 5_1_37FAA, Lachnospiraceae
6_1_63FAA, Lachnospiraceae 9_1_43BFAA, Lachnospiraceae sp 5_1_63FAA,
Lachnospiraceae
splanchnicus

8_1_57FAA,

DSM

Parabacteroides

20712,

merdae

Olsenella

DSM

uli

Parabacteroides

ATCC

43184,

7084,

distasonis

Odoribacter

ATCC

8503,

sp.

D13,

Parabacteroides

Phascolarctobacterium sp YIT 12067, Prevotella bryantii B14, Roseburia
intestinalis L1-82, Roseburia intestinalis M50/1, Roseburia intestinalis XB6B4,
Roseburia inulinivorans DSM 16841, Ruminococcaceae bacterium D16,
Ruminococcus

bromii

L2-63,

Ruminococcus

Ruminococcus

lactaris

ATCC

29176,

gnavus

Ruminococcus

ATCC

29149,

obeum

A2-162,

Ruminococcus obeum ATCC 29174, Ruminococcus torques ATCC 27756,
Ruminococcus

torques

L2-14,

Slackia

exigua

ATCC

700122,

Slackia

heliotrinireducens DSM 20476, Turicibacter sanguinis PC909.
Short chain fatty acid determination
SCFAs were determined based on approaches described by Campbell and
coworkers (1997), with slight modifications. Undiluted fecal samples were
removed from storage at -80°C and thawed on ice, and 0.4 g were diluted in 2.8
ml water containing 5-10 mM 4-methylvaleric acid and vortexed. 0.4 ml of 25%
(w/v) metaphosphoric acid was added and the sample was vortexed again,
followed by centrifugation for 20 min at 15,000 x g. The supernatant was stored
overnight at -20°C. Samples were thawed and centrifuged in the same conditions
as before. SCFA were quantified by gas chromatography (Perkin Elmer Clarus
with Perkin Elmer Elite-FFAP column) in a 4 μl injection volume, and the data
was analyzed with appropriate software (TotalChrom, Perkin Elmer, USA).
Moisture quantification in the fecal samples was done as follows. Approximately
0.2 g of feces was introduced into a plastic tube with a small perforation in its cap
and frozen overnight at -20°C. Samples were freeze dried for at least 36 hours

until stable weight of the sample was achieved, and dry weight was calculated.
SCFA were expressed on a dry basis.
Statistics
Correlations between host parameters and bacterial populations were assessed
by Pearson’s correlation test (GraphPad Prism v5.0). Graphs were generated for
parameters that showed significant correlations and were visually inspected. If
the removal of one single data-point caused the association to become nonsignificant, the data point was considered an outlier and removed.
Associations between inflammatory markers and members of the gut microbiome
were further analyzed with the following linear models:
Iijt = β0 + β1Fat + β2Gender + β3Age + β4T2 + β5T3 + β6T4

(1)

Mhjt = β0 + β1Fat + β2Gender + β3Age + β4T2 + β5T3 + β6T4 (2)
ijt is the inflammatory marker i for subject j in treatment t, i=1,2,3; j=1…28;
hjt is the inflammatory marker h for subject j in treatment t, h=1,…,80; j=1…28;
t=1,2,3,4; Fat indicates the percent body fat; Gender is a binary variable that
takes values of 0 if the subject is female and 1 otherwise; Age is the age of
subject in years; T2 is a binary variable that assigns 1 if the treatment is 30
grams of B and BR each and 0 otherwise; T3 is a binary variable that assigns 1 if
the treatment is 60 grams of B and 0 otherwise; T4 is a binary variable that
assigns 1 if the treatment is 60 grams of BR and 0 otherwise; and T1 represents
no treatment and is left out of the models as the base. Fixed effects and random
effects methods were used to estimate models (1) and (2). Chi-square estimates
that measure the heterogeneity of the responses clustered by subject, were used
as the criterion for choice between fixed and random effects estimation methods.
For the models with Chi-square values associated with P < 0.1, random effects
method was chosen.

Because hs-CRP concentrations >10 mg/l in plasma are indicative of acute
inflammation unrelated to cardiovascular disease risk (Pearson et al., 2003).
Therefore, 4 samples from 4 different subjects were excluded from the analysis.
If the same samples also displayed abnormally high values of LBP or IL-6 levels,
these data points were also considered outliers and removed. 2 and 3 samples
were excluded from LBP and IL-6 analysis, respectively. One subject was
excluded from the analysis of glucose parameters as incomplete data was
obtained for this subject.
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Table S1. Nutritional information of the barley and brown rice flakes used in
the study.
Whole grain
barley

Brown rice

Calories (kcal per 100g)

392

366

Fat (%)

6.7

3.0

Saturated fat (%)

1.7

1.0

Cholesterol (%)

0.0

0.0

Total carbohydrates (%)

64.6

80.0

Digestible starch b (%)

32.3

83.3

0.2

0.5

31.1

7.3

22.8

6.8

Soluble fiber (%)

8.3

0.5

Β‐glucan d (%)

14.1

0.0

18.2

8.0

b

Resistant starch (%)
c

Total dietary fiber (%)
c

Insoluble fiber (%)
c

Protein (%)
a
b
C

Nutrient composition as provided by the manufacturers except when specifically noted.
Measured with K-RSTAR Megazyme kit. (Expressed as dry basis).
Measured according to AACCI Approved Method 32-25.01 with modifications from Andersson et al.

(1999). (Expressed as dry basis).
d

Measured with K-BGLU Megazyme kit. (Expressed as dry basis).

Table S2. List of bacterial species possessing β-glucanase genes and/or
that responded to whole grain barley. Bacterial genomes containing βglucanase genes were identified using the Integrated Microbial Genomes system
(IMG). The number and types of β-glucanases are indicated for the individual
species. The number of subjects in which the species was detected and the
direction of the shifts in response to WGB intake are presented. Abundances of
species as a percentage of total fecal microbiota are also shown (mean ± SD).

Bacterial species

Number and type of enzymes
encoded

Number of
subjects
in which
detected

Response to
WGB in
individual
subjects

Baseline
(mean ± SD)

BR
(mean ± SD)

BR+WGB
(mean ± SD)

WGB
(mean ± SD)

(ANOVA)

Abundance (% of total microbiota)

P-value

Akkermansia muciniphila

2 β-glucanase precursor

10

10 no pattern

0.84 ± 1.82

0.57 ± 1.3

0.34 ± 0.86

0.41 ± 0.66

NS

Bacteroides caccae

7 β-glucanase/β-glucanase synthase

17

17 no pattern

0.2 ± 0.75

0.09 ± 0.21

0.13 ± 0.31

0.13 ± 0.43

NS

Bacteroides coprocola

4 endoglucanase
2 β-glucanase/β-glucanase synthase

3

2↑
1 no pattern

0.37 ± 1.52

0.14 ± 0.5

1.06 ± 3.73

1.24 ± 4.68

NS

Bacteroides dorei

1 β-glucanase
2 β-glucanase/β-glucanase synthase

24

24 no pattern

1.88 ± 3.81

1.60 ± 2.90

1.37 ± 2.75

1.34 ± 2.84

NS

Bacteroides finegoldii

2 β-glucanase/β-glucanase synthase

4

4 no pattern

0.04 ± 0.2

0.06 ± 0.19

0.06 ± 0.33

0.02 ± 0.08

NS

Bacteroides fragilis

9 β-glucanase precursor
3 putative β-glucanase precursor

18

1↓
17 no pattern

2.68 ± 8.12

1.81 ± 6.04

1.60 ± 5.05

1.21 ± 4.56

NS

Bacteroides intestinalis

2 β-glucanase/β-glucanase synthase
6 endoglucanase

25

3↑
22 no pattern

0.32 ± 0.55

0.93 ± 2.66

0.38 ± 0.69

0.47 ± 0.76

NS

Bacteroides ovatus

2 β-glucanase/β-glucanase synthase
6 endoglucanase

ND

Bacteroides thetaiotamicron

3 β-glucanase precursor
2 endoglucanase E precursor

25

25 no pattern

0.57 ± 0.79

0.72 ± 1.38

0.52 ± 0.98

0.40 ± 0.52

NS

Bacteroides uniformis

1 β-glucanase/β-glucanase synthase
8 endoglucanase

26

1↑
3↓
22 no pattern

4.55 ± 4.55

3.34 ± 3.3

2.77 ± 3.38

3.57 ± 4.59

NS

Bacteroides eggerthii

2 endoglucanase

7

1↑
6 no pattern

0.35 ± 1.39

0.36 ± 1.03

0.32 ± 1.15

0.33 ± 0.97

NS

Blautia wexlerae

No matches found

28

6↑
1↓
11 no pattern

1.07 ± 0.78

1.58 ± 1.11

1.49 ± 0.98

¶¶¶*

1.82 ± 1.14

< 0.0001

Blautia hydrogenotrophica

No matches found

4

4 no pattern

0.00 ± 0.01

0.00 ± 0.01

0.00 ± 0.02

0.00 ± 0.01

NS

Blautia coccoides

No matches found

7

7 no pattern

0.01 ± 0.02

0.00 ± 0.01

0.00 ± 0.01

0.01 ± 0.02

NS

Blautia producta

No matches found

4

4 no pattern

0.01 ± 0.03

0.00 ± 0.01

0.00 ± 0.01

0.00 ± 0.01

NS

Blautia hansenii

No matches found

5

5 no pattern

0.10 ± 0.26

0.05 ± 0.16

0.18 ± 0.91

0.08 ± 0.34

NS

Blautia spp. (Ruminococccus
obeum)

1,3-beta-glucosidase

14

4↑
10 no pattern

1.81 ± 1.13

2.38 ± 1.69

2.75 ± 1.75

¶

2.80 ± 2.04

¶¶

0.006

Bifidobacterium adolescentis

2 putative β-1,3-endoglucanase
2 endoglucanase

14

2↑
12 no pattern

0.22 ± 0.42

0.36 ± 0.83

0.64 ± 1.3

0.48 ± 1.08

NS

Bifidobacterium angulatum

2 endoglucanase

ND

Bifidobacterium longum

1 putative β-1,3-exoglucanase
2 endoglucanase

17

1↑
16 no pattern

0.16 ± 0.42

0.17 ± 0.50

0.18 ± 0.33

0.23 ± 0.50

NS

Bifidobacterium
pseudocatenulatum

4 endoglucanse

7

7 no pattern

0.07 ± 0.22

0.14 ± 0.65

0.08 ± 0.24

0.07 ± 0.20

NS

Clostridium butyricum

7 endoglucanase

4

4 no pattern

0.01 ± 0.03

0.00 ± 0.01

0.00 ± 0.01

0.00 ± 0.01

NS

Clostridium ramosum

2 β-glucanase/β-glucanase synthase
2 endoglucanase

ND

Collinsella aerofaciens

2 endoglucanase

17

17 no pattern

0.08 ± 0.22

0.14 ± 0.28

0.1 ± 0.19

0.08 ± 0.18

NS

Collinsella intestinalis

2 endoglucanase

ND

Collinsella stercoris

2 endoglucanase

ND

Coprococcus comes

2 endoglucanase

25

1↑
24 no pattern

0.29 ± 0.38

0.35 ± 0.42

0.33 ± 0.48

0.29 ± 0.45

NS

Coprococcus eutactus

1 β-glucanase/β-glucanase synthase
8 endoglucanase

13

1↑
12 no pattern

0.68 ± 1.23

0.64 ± 1.23

0.62 ± 1.29

0.75 ± 1.35

NS

Dialister invisus

No matches found

0.52 ± 0.97

0.41 ± 0.72

0.56 ± 0.86

0.81 ± 1.41

Eubacterium eligens

1 putative endoglucanase

14

2↑
12 no pattern

0.22 ± 0.42

0.36 ± 0.83

0.64 ± 1.3

0.48 ± 1.08

Eubacterium rectale

1 endo-1,4-β-glucanase

28

14 ↑
14 no pattern

2.48 ± 2.67

2.75 ± 3.27

3.65 ± 3.45

Roseburia inulinivorans

1 endo-1,4-β-glucanase

28

1↑
27 no pattern

0.25 ± 0.3

0.21 ± 0.32

0.14 ± 0.24

Roseburia faecis

Not in database

27

10 ↑
17 no pattern

0.12 ± 0.17

0.06 ± 0.07

0.26 ± 0.31

0.53 ± 0.92

Roseburia intestinalis

5 endo-1,4-β-glucanase

28

9↑
19 no pattern

0.09 ± 0.12

0.04 ± 0.05

0.17 ± 0.18

Ŧ

0.30 ± 0.42

ND: Not detected; NS: Not significant.

4.83 ± 3.98

¶ŦŦ*

0.16 ± 0.18

NS
0.001
NS

¶¶ŦŦŦ

< 0.0001

¶ŦŦŦ

< 0.0001

Table S3. Treatment effect on metabolic and immunological markers for all
subjects. Metabolic data of the 28 participants, at baseline and at the end of the
4-week dietary treatments (BR, BR+WGB, WGB). Values are presented as mean
± SD.
Overall
Cholesterol
Total cholesterol (mmol/l)
Non-HDL (mmol/l)
HDL (mmol/l)
Plasma glucose
Fasting (mmol/l)
2

AUC ([mmol/l] )
Max. peak (mmol/l)
Plasma insulin
Fasting (μUI/ml)
AUC ([μUI/ml]2)
Max. peak (μUI/ml)
Inflammatory markers
IL-6 (pg/ml)
Hs-CRP (mg/L)
LBP (μg/ml)

Baseline

BR

BR+WGB

WGB

P-value

4.86 ± 1.15
3.09 ± 1.04
1.63 ± 0.43

4.76 ± 0.79
3.15 ± 0.84
1.60 ± 0.37

4.56 ± 0.89
3.00 ± 0.85
1.55 ± 0.45

4.89 ± 0.94
3.32 ± 0.94
1.57 ± 0.36

NS
NS
NS

5.15 ± 0.73

4.87 ± 0.49

4.81 ± 0.39

4.81 ± 0.50

NS

784 ± 184
9.08 ± 2.78

763 ± 164
8.58 ± 2.02

746 ± 132
7.92 ± 1.46

770 ± 179
8.19 ± 2.35

NS
< 0.1

6.77 ± 1.96

6.60 ± 2.13

6.51 ± 2.02

7.03 ± 2.07

NS

3463 ± 1523
44.08 ± 19.19

3606 ± 1520
44.70 ± 19.56

3333 ± 1035
42.86 ± 14.49

3540 ± 1481
45.13 ± 21.61

NS
NS

1.68 ± 1.36
1.60 ± 2.23
14.41 ± 19.65

1.21 ± 0.99
1.33 ± 1.65
14.39 ± 2.09

0.90 ± 0.45*
0.95 ± 1.23
13.23 ± 19.04

1.12 ± 0.63
1.36 ± 1.88
13.78 ± 18.30

0.0295
NS
NS

*P < 0.05 compared to Baseline.

Table S4. Treatment effect on metabolic and immunological markers in the subjects according to gender.
Metabolic data of the female and male volunteers, at baseline and at the end of the 4-week dietary treatments (BR,
BR+WGB, WGB). Values are presented as mean ± SD.
Males
Baseline

Females

BR

BR+WGB

WGB

P-value

Baseline

BR

BR+WGB

WGB

P-value

Cholesterol
Total cholesterol (mmol/l)

4.42 ± 1.11

4.59 ± 0.85

4.31 ± 0.91

4.46 ± 0.89

NS

5.02 ± 1.14

4.87 ± 0.76

4.73 ± 0.87

5.15 ± 0.89

0.0342

Non-HDL (mmol/l)

2.78 ± 0.74

3.01 ± 0.96*

2.90 ± 0.93

3.08 ± 0.82

0.0327

3.29 ± 1.16

3.24 ± 0.78

3.06 ± 0.83

3.47 ± 1.00

NS

HDL (mmol/l)

1.30 ± 0.28

1.41 ± 0.30

1.33 ± 0.31

1.23 ± 0.24

NS

1.84 ± 0.37

1.73 ± 0.36

1.69 ± 0.48

1.76 ± 0.25

NS

5.14 ± 0.72

5.10 ± 0.64

4.91 ± 0.39

4.86 ± 0.34

NS

5.15 ± 0.76

4.72 ± 0.29

4.75 ± 0.40

4.77 ± 0.59

0.0344

Plasma glucose
Fasting (mmol/l)
2

AUC ([mmol/l] )
Max. peak (mmol/l)

860 ± 232

851 ± 143

762 ± 166

857 ± 180

NS

739 ± 138

706 ± 155

735 ± 110

718 ± 162

NS

10.13 ± 3.25

10.08 ± 1.67

8.21 ± 1.80

8.99 ± 2.37

< 0.1

8.40 ± 2.27

7.61 ± 1.61

7.74 ± 1.23

7.66 ± 2.26

NS

Plasma insulin
Fasting (μUI/ml)

6.63 ± 1.75

5.93 ± 1.90

6.38 ± 1.80

6.05 ± 2.12

NS

6.85 ± 2.12

7.04 ± 2.22

6.60 ± 2.20

7.66 ± 1.83

NS

AUC ([μUI/ml] )

3436 ± 1787

3816 ± 1704

3399 ± 1086

3600 ± 1586

NS

3480 ± 1405

3483 ± 1442

3294 ± 1037

3505 ± 1465

NS

Max. peak (μUI/ml)

42.76 ± 20.55

48.63 ± 19.14

41.46 ± 12.37

48.54 ± 22.37

NS

44.93 ± 18.86

42.15 ± 19.98

43.76 ± 16.01

42.92 ± 21.50

NS

1.18 ± 0.81

1.42 ± 1.35

1.99 ± 3.63

1.09 ± 0.58

NS

2.01 ± 1.58

1.16 ± 0.83*

1.10 ± 0.86**

1.67 ± 2.39*

0.0028

2

Inflammatory markers
IL-6 (pg/ml)
Hs-CRP (mg/L)

0.35 ± 0.22

0.92 ± 1.26

0.31 ± 0.24

0.76 ± 1.07

NS

2.35 ± 2.56

1.57 ± 1.85

1.33 ± 1.43

1.72 ± 2.19

NS

LBP (μg/ml)

4.76 ± 2.96

6.50 ± 5.48

4.42 ± 2.22

6.19 ± 4.09

NS

20.44 ± 23.19

19.32 ± 25.62

18.73 ± 22.74

18.52 ± 22.04

NS

*P < 0.05 compared to Baseline.
**P < 0.01 compared to Baseline.

Table S5. Treatment effect on metabolic and immunological markers in normoweight and overweight subjects.
Metabolic data of normoweight and overweight, at baseline and at the end of the 4-week dietary treatments (BR,
BR+WGB, WGB). Values are presented as mean ± SD.
Overweight

Normoweight

Baseline

BR

BR+WGB

WGB

P-value

Baseline

BR

BR+WGB

WGB

P-value

Total cholesterol (mmol/l)

4.84 ± 1.26

4.84 ± 0.86

4.51 ± 0.89

5.03 ± 1.05

NS

4.75 ± 1.07

4.69 ± 0.75

4.61 ± 0.92

4.77 ± 0.84

NS

Non-HDL (mmol/l)

3.24 ± 1.21

3.35 ± 0.97

3.12 ± 0.90

3.52 ± 1.05

NS

2.94 ± 0.85

2.98 ± 0.71

2.89 ± 0.83

3.14 ± 0.83

NS

HDL (mmol/l)

1.61 ± 0.45

1.47 ± 0.32

1.37 ± 0.40

1.51 ± 0.35

NS

1.65 ± 0.42

1.72 ± 0.38

1.71 ± 0.45

1.62 ± 0.37

NS

Cholesterol

Plasma glucose
Fasting (mmol/l)

5.37 ± 0.93

4.87 ± 0.45*

4.88 ± 0.37

4.88 ± 0.42

0.0231

4.94 ± 0.40

4.87 ± 0.54

4.75 ± 0.42

4.74 ± 0.57

NS

AUC ([mmol/l] )

867 ± 184

800 ± 187

774 ± 128

811 ± 160

NS

707 ± 153

730 ± 140

720 ± 135

731 ± 192

NS

Max. peak (mmol/l)

9.66 ± 2.14

8.53 ± 2.11

7.99 ± 1.32*

8.43 ± 1.79

0.0428

8.58 ± 3.09

7.86 ± 1.62

7.98 ± 2.80

8.63 ± 2.01

NS

2

Plasma insulin
Fasting (μUI/ml)

6.93 ± 1.70

7.10 ± 2.53

6.82 ± 1.78

7.60 ± 1.58

NS

6.62 ± 2.22

6.17 ± 1.69

6.24 ± 2.24

6.54 ± 2.36

NS

AUC ([μUI/ml] )

3730 ± 1677

3952 ± 1665

3249 ± 1128

3804 ± 1482

NS

3216 ± 1382

3284 ± 1354

3411 ± 978

3295 ± 1493

NS

Max. peak (μUI/ml)

48.39 ± 19.92

50.23 ± 22.63

43.19 ± 16.16

49.94 ± 21.17

NS

40.34 ± 18.38

39.90 ± 15.67

42.57 ± 13.45

40.96 ± 26.83

NS

IL-6 (pg/ml)

2.03 ± 1.32

1.64 ± 1.27

0.97 ± 0.52*

1.40 ± 0.77

0.0438

1.35 ± 1.36

0.81 ± 0.32

0.83 ± 0.38

0.86 ± 0.32

NS

Hs-CRP (mg/L)

2.26 ± 2.47

2.12 ± 1.96

1.37 ± 1.52

1.86 ± 1.87

NS

1.04 ± 1.93

0.66 ± 0.99

0.59 ± 0.83

0.94 ± 1.86

NS

22.45 ± 24.90

23.56 ± 26.42

21.63 ± 23.90

22.16 ± 22.66

NS

6.36 ± 6.67

4.83 ± 5.58

5.40 ± 5.63

5.21 ± 6.83

NS

2

Inflammatory markers

LBP (μg/ml)

*P < 0.05 compared to Baseline.

Table S6. Gastrointestinal symptoms. Weekly gastrointestinal symptoms of
the 28 participating subjects, scored in a scale from 1 (best/normal) to 5
(worst/abnormal) during the baseline and at the end of each 4-week dietary
treatment (BR, BR+WGB, WGB). Values are presented as mean ± SD.
Bowel movement

Baseline

BR

BR+WGB

WGB

1.5 ± 0.5

1.3 ± 0.5

1.7 ± 0.6

2.0 ± 0.8¶ŦŦ

1.8 ± 0.6
1.5 ± 0.6

¶ŦŦ

Stool consistency
General well-being

1.5 ± 0.6
1.2 ± 0.3

1.4 ± 0.5
1.2 ± 0.4

Flatulence

1.3 ± 0.5

1.4 ± 0.5

Abdominal pain

1.1 ± 0.2

1.1 ± 0.3

Bloating
¶ Compared to baseline
Ŧ Compared to BR

1.2 ± 0.4

1.2 ± 0.4

2.2 ± 0.9

¶¶¶ŦŦŦ

1.4 ± 0.6
¶Ŧ

1.6 ± 0.7

P-value
< 0.01

2.0 ± 0.8
2.2 ± 0.6¶¶¶ŦŦŦ**

< 0.01
< 0.001

3.1 ± 1.0¶¶¶ŦŦŦ***

< 0.001

¶¶¶ŦŦŦ*

< 0.001

¶¶¶ŦŦŦ**

< 0.001

1.8 ± 0.8
2.2 ±0.8

Supplementary Figures
Figure S1. Association between inflammatory and metabolic markers and
bacterial taxa in fecal samples. A heat map shows correlation coefficients
(Pearson) between BMI, percent body fat, IL-6, hs-CRP, LBP and glucose AUC
with proportions of bacterial taxa in fecal samples.
Figure S2. Associations between Bacteroidetes related taxa and HDL
plasma levels at baseline. Correlations between proportions of Bacteroidetes
(A), Bacteroidaceae (B) and Bacteroides (C) in fecal samples with HDL
measured in plasma at baseline. Pearson’s r correlation and the P values are
presented.
Figure S3. Impact of whole grains on the fecal microbiota. Diversity of the
bacterial population in fecal samples assessed by Shannon’s (A) and Simpson’s
(B) α-diversity indices. * P < 0.05, ** P < 0.01.
Figure S4. Association between diet induced shifts in glycemic response
and the proportion of Eubacterium rectale. Correlation of the shift of the
Eubacterium rectale abundance with the shifts observed in postprandial AUC (A),
Insulin AUC (B), and maximum glucose levels (C). Shift refers to differences
between values obtained during the BR+B period and the baseline. Pearson’s r
correlation and the P values are presented.
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